Ilaris(canakinumab)
Ilaris (canakinumab) is an antibody pharmaceutical. Canakinumab was first approved as Ilaris on 2009-06-17. It is used to treat cryopyrin-associated periodic syndromes, familial mediterranean fever, juvenile arthritis, and mevalonate kinase deficiency in the USA. It has been approved in Europe to treat arthritis, cryopyrin-associated periodic syndromes, and gouty arthritis. The pharmaceutical is active against interleukin-1 beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ilaris
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ilaris | Biologic Licensing Application | 2024-06-13 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
canakinumab, Ilaris, Novartis Pharmaceuticals Corporation | |||
| 2027-06-16 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0638 | Injection, canakinumab, 1 mg |
Clinical
Clinical Trials
111 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | HP_0001369 | M05-M14 | 3 | 9 | 11 | 1 | 1 | 22 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 6 | — | 1 | — | 7 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | — | 1 | — | 1 |
| Spondylarthritis | D025241 | — | — | — | — | — | 1 | — | 1 |
| Spondylitis | D013166 | — | M46.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 2 | 7 | 9 | — | 3 | 20 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | 1 | 2 | 7 | — | — | 9 |
| Gouty arthritis | D015210 | — | — | — | 2 | 5 | — | 1 | 8 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 4 | 4 | — | — | 8 |
| Cryopyrin-associated periodic syndromes | D056587 | — | M04.2 | — | — | 7 | — | 1 | 8 |
| Fever | D005334 | HP_0001945 | R50.9 | 1 | 3 | 3 | — | — | 7 |
| Covid-19 | D000086382 | — | — | — | 1 | 2 | — | 3 | 6 |
| Familial mediterranean fever | D010505 | — | M04.1 | 1 | 2 | 3 | — | — | 6 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | 3 | — | — | 6 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 5 | 1 | — | — | 6 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 3 | — | — | — | 4 |
| Preleukemia | D011289 | — | — | 2 | 3 | — | — | — | 4 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 3 | — | — | — | 3 |
| Schnitzler syndrome | D019873 | EFO_1001165 | — | — | 3 | — | — | — | 3 |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | — | 1 | — | — | 1 | 2 |
| Brucellosis | D002006 | EFO_0007185 | A23 | — | 2 | — | — | — | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | — | — | — | 2 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | — | — | — | — | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Canakinumab |
| INN | canakinumab |
| Description | Immunoglobulin G1, anti-[Homo sapiens interleukin 1, beta (IL1B)] human monoclonal ACZ885; gamma1 heavy chain (Homo sapiens VH-IGHG1*03) (221-214’)-disulfide with kappa light chain (Homo sapiens V-KAPPA-IGKC*01); (227-227’’:230-230’’)-bisdisulfide dimer |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4G5Z:H|canakinumab antibody fragment heavy chain
QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPAKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLY
LQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVAP
>4G5Z:L|canakinumab antibody fragment light chain
EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEA
EDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG |
Identifiers
| PDB | 4G5Z, 4G6J, 5BVJ, 5BVP |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201834 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06168 |
| UNII ID | 37CQ2C7X93 (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Ilaris – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,214 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,615 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use